

argenx to Report Half Year 2025 **Financial Results and Second** Quarter Business Update on July 31, 2025

Your publication date and time will appear here.

| Source: argenx

SE

Share

July 24, 2025













Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

32 800 50 201 Belgium France 33 800 943355 31 20 795 1090 Netherlands 44 800 358 0970 United Kingdom **United States** 1 888 415 4250 Japan 81 3 4578 9081 Switzerland 41 43 210 11 32

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a worldclass portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. information, For more visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and <u>YouTube</u>.

Contacts

Media:

Ben Petok

bpetok@argenx.com

Investors:

Alexandra Roy

aroy@argenx.com